The proportion of patients with hormone receptor-positive breast cancer (estrogen receptor + and/or progesterone receptor+) was lower in the eligible group than in the ineligible group (58.8% vs. 79.3%, p = 0.024); otherwise, there was no significant difference in patient characteristics between groups. The gene discussed is ESR1; the disease is breast carcinoma.